lebrikizumab

As a noun lebrikizumab is

a humanized monoclonal antibody and immunosuppressive drug being investigated for the treatment of asthma.

As nouns the difference between asthma and lebrikizumab

is that asthma is while lebrikizumab is a humanized monoclonal antibody and immunosuppressive drug being investigated for the treatment of asthma.

As nouns the difference between drug and lebrikizumab

is that drug is (pharmacology) a substance used to treat an illness, relieve a symptom, or modify a chemical process in the body for a specific purpose or drug can be (obsolete) a drudge while lebrikizumab is a humanized monoclonal antibody and immunosuppressive drug being investigated for the treatment of asthma.

As a verb drug

is to administer intoxicating drugs to, generally without the recipient's knowledge or consent or drug can be (drag).

As nouns the difference between immunosuppressive and lebrikizumab

is that immunosuppressive is (pharmacology) an agent which is capable of immunosuppression while lebrikizumab is a humanized monoclonal antibody and immunosuppressive drug being investigated for the treatment of asthma.

As an adjective immunosuppressive

is (pharmacology) having the capability to suppress the immune system, capable of immunosuppression.

As a verb humanized

is (humanize).

As a noun lebrikizumab is

a humanized monoclonal antibody and immunosuppressive drug being investigated for the treatment of asthma.